Development and implementation of novel liquid biopsy NGS panels via the OncNGS precommercial procurement (PCP) initiative
Health and disease monitoring
Quality of healthcare
Download 300.35 KBAuthors
Gordana Raicevic [3]; R. Alessandrello [4]; P. Giacomini [5]; M. Kamal [6]; M. Gausachs [7]; L. Mazzarella [8]; P. Sujobert [9]; G. Frigè [10]; A. Alay [11]; J.M. Planchon [12]; O. Blau [13]; M.R. Mias Carballal [14]; H Antoine-Poirel [15]; E. Nadal [16]; L. Bullinger [17]; Aline Hébrant [18]; N. Servant [19]; N. D’Haene [20]; P. Aftimos [21]; E. Silkenstedt [22]; A. Michalík [23]; C. Dupain [24]; T. Delcourt [25]; S. Huet [26]; C. Van Campenhout [27]; Cordero, D. [28]; Garcia J.M. Castellano [29]; C. Codony [30]; A. Krol [31]; J. Gonzalo [32]; N. Van Damme [33]; Marie Delnord [34]; R. Carbone [35]; V. Trapani [36]; S. Van Garsse [37]; M Van Den Bulcke [38]Keywords
Article written during project(s) :
Abstract:
Background
Circulating tumor DNA (ctDNA) analysis is transforming oncology, but challenges such as insufficient analytical sensitivity, difficult variant interpretation, suboptimal turnaround time, limited deployment flexibility, and high costs hinder its broader adoption and raise concerns about reimbursement sustainability across European health care systems.
Materials and methods
To address these challenges, we created the OncNGS consortium, comprising academic, public, and private hospitals (buyers’ group) and several supporting entities, to run a European precommercial procure…